Do analysts prefer TLSI or DXR?

TriSalus Life Sciences presently has a consensus price target of $7.50, suggesting a potential upside of 86.10%. Given TriSalus Life Sciences' higher probable upside, equities analysts plainly believe TriSalus Life Sciences is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TriSalus Life Sciences 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings and valuation, TLSI or DXR?

Daxor has lower revenue, but higher earnings than TriSalus Life Sciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TriSalus Life Sciences $45.15M 5.48 -$39.23M -$1.41 N/A Daxor $10.30M 5.75 N/A N/A N/A

Is TLSI or DXR more profitable?

Daxor has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences -60.85% N/A -69.91% Daxor N/A N/A N/A

Does the media refer more to TLSI or DXR?

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Daxor. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 1 mentions for Daxor. TriSalus Life Sciences' average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend SMTI or DXR?

Sanara MedTech currently has a consensus price target of $34.00, indicating a potential upside of 56.32%. Given Sanara MedTech's stronger consensus rating and higher probable upside, research analysts plainly believe Sanara MedTech is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanara MedTech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, SMTI or DXR?

Daxor has lower revenue, but higher earnings than Sanara MedTech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sanara MedTech $103.12M 1.93 -$37.56M -$3.77 N/A Daxor $10.30M 5.75 N/A N/A N/A

Does the media favor SMTI or DXR?

In the previous week, Sanara MedTech had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Sanara MedTech and 1 mentions for Daxor. Sanara MedTech's average media sentiment score of 1.78 beat Daxor's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanara MedTech 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer LUCD or DXR?

Lucid Diagnostics presently has a consensus target price of $4.19, suggesting a potential upside of 306.55%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lucid Diagnostics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has better earnings and valuation, LUCD or DXR?

Daxor has higher revenue and earnings than Lucid Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lucid Diagnostics $5.13M 40.74 -$58.01M -$0.47 N/A Daxor $10.30M 5.75 N/A N/A N/A

Is LUCD or DXR more profitable?

Daxor has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%. Company Net Margins Return on Equity Return on Assets Lucid Diagnostics -876.72% N/A -116.26% Daxor N/A N/A N/A

Do analysts recommend DXR or PDEX?

Pro-Dex has a consensus target price of $70.00, indicating a potential upside of 10.43%. Given Pro-Dex's higher probable upside, analysts clearly believe Pro-Dex is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Pro-Dex 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation & earnings, DXR or PDEX?

Pro-Dex has higher revenue and earnings than Daxor. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor $10.30M 5.75 N/A N/A N/A Pro-Dex $66.59M 3.04 $8.98M $3.62 17.51

Is DXR or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Daxor's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Pro-Dex 16.08% 22.78% 14.30%

Does the media prefer DXR or PDEX?

In the previous week, Pro-Dex had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for Daxor. Daxor's average media sentiment score of 0.00 equaled Pro-Dex'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pro-Dex 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer DXR or APYX?

Apyx Medical has a consensus price target of $6.50, suggesting a potential upside of 59.31%. Given Apyx Medical's stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than Daxor. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Daxor 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Apyx Medical 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has better earnings & valuation, DXR or APYX?

Daxor has higher earnings, but lower revenue than Apyx Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Daxor $10.30M 5.75 N/A N/A N/A Apyx Medical $55.90M 3.06 -$11.21M -$0.22 N/A

Is DXR or APYX more profitable?

Daxor has a net margin of 0.00% compared to Apyx Medical's net margin of -16.40%. Daxor's return on equity of 0.00% beat Apyx Medical's return on equity. Company Net Margins Return on Equity Return on Assets Daxor N/A N/A N/A Apyx Medical -16.40% -88.47% -14.94%

Does the media refer more to DXR or APYX?

In the previous week, Apyx Medical had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Apyx Medical and 1 mentions for Daxor. Apyx Medical's average media sentiment score of 1.05 beat Daxor's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Daxor 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apyx Medical 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Daxor (DXR) Competitors

$10.14 +0.64 (+6.74%)

As of 06/23/2026 03:27 PM Eastern

Compare

DXR vs. TLSI, SMTI, LUCD, PDEX, and APYX

Should you buy Daxor stock or one of its competitors? MarketBeat compares Daxor with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Daxor include TriSalus Life Sciences (TLSI), Sanara MedTech (SMTI), Lucid Diagnostics (LUCD), Pro-Dex (PDEX), and Apyx Medical (APYX). These companies are all part of the "medical equipment" industry.

How does Daxor compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, media sentiment, profitability, analyst recommendations, institutional ownership and valuation.

TriSalus Life Sciences has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, Daxor has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

In the previous week, TriSalus Life Sciences had 2 more articles in the media than Daxor. MarketBeat recorded 3 mentions for TriSalus Life Sciences and 1 mentions for Daxor. TriSalus Life Sciences' average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Daxor has lower revenue, but higher earnings than TriSalus Life Sciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	5.48	-$39.23M	-$1.41	N/A
Daxor	$10.30M	5.75	N/A	N/A	N/A

Daxor has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
Daxor	N/A	N/A	N/A

TriSalus Life Sciences presently has a consensus price target of $7.50, suggesting a potential upside of 86.10%. Given TriSalus Life Sciences' higher probable upside, equities analysts plainly believe TriSalus Life Sciences is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 51.5% of Daxor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

TriSalus Life Sciences beats Daxor on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to Sanara MedTech?

Sanara MedTech (NASDAQ:SMTI) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

Sanara MedTech currently has a consensus price target of $34.00, indicating a potential upside of 56.32%. Given Sanara MedTech's stronger consensus rating and higher probable upside, research analysts plainly believe Sanara MedTech is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sanara MedTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Sanara MedTech had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Sanara MedTech and 1 mentions for Daxor. Sanara MedTech's average media sentiment score of 1.78 beat Daxor's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sanara MedTech	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.1% of Sanara MedTech shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 42.0% of Sanara MedTech shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Daxor has a net margin of 0.00% compared to Sanara MedTech's net margin of -31.23%. Daxor's return on equity of 0.00% beat Sanara MedTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sanara MedTech	-31.23%	-3.19%	-0.56%
Daxor	N/A	N/A	N/A

Sanara MedTech has a beta of 1.21, meaning that its stock price is 21% more volatile than the broader market. Comparatively, Daxor has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Daxor has lower revenue, but higher earnings than Sanara MedTech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sanara MedTech	$103.12M	1.93	-$37.56M	-$3.77	N/A
Daxor	$10.30M	5.75	N/A	N/A	N/A

Summary

Sanara MedTech beats Daxor on 9 of the 14 factors compared between the two stocks.

How does Daxor compare to Lucid Diagnostics?

Lucid Diagnostics (NASDAQ:LUCD) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Lucid Diagnostics presently has a consensus target price of $4.19, suggesting a potential upside of 306.55%. Given Lucid Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lucid Diagnostics is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Daxor has higher revenue and earnings than Lucid Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lucid Diagnostics	$5.13M	40.74	-$58.01M	-$0.47	N/A
Daxor	$10.30M	5.75	N/A	N/A	N/A

Daxor has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -876.72%.

Company	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-876.72%	N/A	-116.26%
Daxor	N/A	N/A	N/A

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by company insiders. Comparatively, 51.5% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Daxor had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 1 mentions for Daxor and 0 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 0.00 equaled Daxor'saverage media sentiment score.

Company	Overall Sentiment
Lucid Diagnostics	Neutral
Daxor	Neutral

Lucid Diagnostics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Daxor has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

Lucid Diagnostics beats Daxor on 6 of the 11 factors compared between the two stocks.

How does Daxor compare to Pro-Dex?

Daxor (NASDAQ:DXR) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

1.3% of Daxor shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 51.5% of Daxor shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pro-Dex has a net margin of 16.08% compared to Daxor's net margin of 0.00%. Pro-Dex's return on equity of 22.78% beat Daxor's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Pro-Dex	16.08%	22.78%	14.30%

Daxor has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market. Comparatively, Pro-Dex has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

Pro-Dex has a consensus target price of $70.00, indicating a potential upside of 10.43%. Given Pro-Dex's higher probable upside, analysts clearly believe Pro-Dex is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pro-Dex has higher revenue and earnings than Daxor.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$10.30M	5.75	N/A	N/A	N/A
Pro-Dex	$66.59M	3.04	$8.98M	$3.62	17.51

In the previous week, Pro-Dex had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Pro-Dex and 1 mentions for Daxor. Daxor's average media sentiment score of 0.00 equaled Pro-Dex'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pro-Dex	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Pro-Dex beats Daxor on 7 of the 11 factors compared between the two stocks.

How does Daxor compare to Apyx Medical?

Daxor (NASDAQ:DXR) and Apyx Medical (NASDAQ:APYX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

In the previous week, Apyx Medical had 3 more articles in the media than Daxor. MarketBeat recorded 4 mentions for Apyx Medical and 1 mentions for Daxor. Apyx Medical's average media sentiment score of 1.05 beat Daxor's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Daxor	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apyx Medical	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

1.3% of Daxor shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 51.5% of Daxor shares are held by company insiders. Comparatively, 15.2% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Daxor has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market.

Apyx Medical has a consensus price target of $6.50, suggesting a potential upside of 59.31%. Given Apyx Medical's stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than Daxor.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Daxor has a net margin of 0.00% compared to Apyx Medical's net margin of -16.40%. Daxor's return on equity of 0.00% beat Apyx Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Apyx Medical	-16.40%	-88.47%	-14.94%

Daxor has higher earnings, but lower revenue than Apyx Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$10.30M	5.75	N/A	N/A	N/A
Apyx Medical	$55.90M	3.06	-$11.21M	-$0.22	N/A

Summary

Apyx Medical beats Daxor on 9 of the 14 factors compared between the two stocks.

Get Daxor News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DXR vs. The Competition

Export

Metric	Daxor	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.46M	$5.72B	$6.44B	$12.30B
Dividend Yield	N/A	1.57%	2.69%	5.83%
P/E Ratio	N/A	36.49	24.65	23.99
Price / Sales	5.75	25.65	535.11	118.14
Price / Cash	N/A	16.98	44.82	54.51
Price / Book	N/A	3.27	10.70	6.50
Net Income	N/A	$218.81M	$3.56B	$336.88M
7 Day Performance	3.21%	2.60%	0.94%	-0.16%
1 Month Performance	-4.11%	3.26%	0.35%	0.76%
1 Year Performance	9.15%	17.73%	29.67%	28.49%

Daxor Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DXR Daxor	2.1938 of 5 stars	$10.14 +6.7%	N/A	+7.2%	$55.46M	$10.30M	N/A	37	News Coverage Gap Up
TLSI TriSalus Life Sciences	2.9412 of 5 stars	$3.64 +2.5%	$7.50 +106.0%	-23.8%	$218.03M	$45.15M	N/A	106
SMTI Sanara MedTech	2.673 of 5 stars	$21.50 -6.5%	$34.00 +58.1%	-21.8%	$210.68M	$103.12M	N/A	60	News Coverage
LUCD Lucid Diagnostics	4.0551 of 5 stars	$0.98 -3.2%	$4.19 +328.1%	-13.4%	$198.62M	$5.13M	N/A	70
PDEX Pro-Dex	2.1189 of 5 stars	$62.92 +1.5%	$70.00 +11.3%	+51.6%	$197.89M	$66.59M	17.38	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DXR) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Daxor (DXR) Competitors

DXR vs. TLSI, SMTI, LUCD, PDEX, and APYX

How does Daxor compare to TriSalus Life Sciences?

Summary

How does Daxor compare to Sanara MedTech?

Summary

How does Daxor compare to Lucid Diagnostics?

Summary

How does Daxor compare to Pro-Dex?

Summary

How does Daxor compare to Apyx Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR vs. The Competition

Daxor Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Daxor (DXR) Competitors

DXR vs. TLSI, SMTI, LUCD, PDEX, and APYX

How does Daxor compare to TriSalus Life Sciences?

Which has more volatility & risk, TLSI or DXR?

Does the media refer more to TLSI or DXR?

Which has stronger earnings and valuation, TLSI or DXR?

Is TLSI or DXR more profitable?

Do analysts prefer TLSI or DXR?

Do institutionals & insiders hold more shares of TLSI or DXR?

Summary

How does Daxor compare to Sanara MedTech?

Do analysts recommend SMTI or DXR?

Does the media favor SMTI or DXR?

Do insiders & institutionals believe in SMTI or DXR?

Is SMTI or DXR more profitable?

Which has more volatility and risk, SMTI or DXR?

Which has stronger valuation and earnings, SMTI or DXR?

Summary

How does Daxor compare to Lucid Diagnostics?

Do analysts prefer LUCD or DXR?

Which has better earnings and valuation, LUCD or DXR?

Is LUCD or DXR more profitable?

Do insiders and institutionals hold more shares of LUCD or DXR?

Does the media favor LUCD or DXR?

Which has more risk & volatility, LUCD or DXR?

Summary

How does Daxor compare to Pro-Dex?

Do insiders & institutionals believe in DXR or PDEX?

Is DXR or PDEX more profitable?

Which has more volatility and risk, DXR or PDEX?

Do analysts recommend DXR or PDEX?

Which has higher valuation & earnings, DXR or PDEX?

Does the media prefer DXR or PDEX?

Summary

How does Daxor compare to Apyx Medical?

Does the media refer more to DXR or APYX?

Do insiders and institutionals hold more shares of DXR or APYX?

Which has more volatility & risk, DXR or APYX?

Do analysts prefer DXR or APYX?

Is DXR or APYX more profitable?

Which has better earnings & valuation, DXR or APYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DXR vs. The Competition

Daxor Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools